Background Immune hyperactivity is an important contributing factor to the morbidity and mortality of COVID-19 infection. Nasal administration of anti-CD3 monoclonal antibody downregulates hyperactive immune responses in animal models of autoimmunity through its immunomodulatory properties. We performed a randomized pilot study of fully-human nasal anti-CD3 (Foralumab) in patients with mild to moderate COVID-19 to determine if its immunomodulatory properties had ameliorating effects on disease. Methods Thirty-nine outpatients with mild to moderate COVID-19 were recruited at Santa Casa de Misericordia de Santos in Sao Paulo State, Brazil. Patients were randomized to three cohorts: 1) Control, no Foralumab (n=16); 2) Nasal Foralumab (100ug/day) given for 10 consecutive days with 6 mg dexamethasone given on days 1-3 (n=11); and 3) Nasal Foralumab alone (100ug/day) given for 10 consecutive days (n=12). Patients continued standard of care medication. Results We observed reduction of serum IL-6 and C-reactive protein in Foralumab alone vs . untreated or Foralumab/Dexa treated patients. More rapid clearance of lung infiltrates as measured by chest CT was observed in Foralumab and Foralumab/Dexa treated subjects vs . those that did not receive Foralumab. Foralumab treatment was well-tolerated with no severe adverse events. Conclusions This pilot study suggests that nasal Foralumab is well tolerated and may be of benefit in treatment of immune hyperactivity and lung involvement in COVID-19 disease and that further studies are warranted.
【저자키워드】 COVID-19, SARS-CoV-2, immune responses, foralumab, anti-CD3, 【초록키워드】 Dexamethasone, Treatment, Brazil, Autoimmunity, immune response, IL-6, lung involvement, monoclonal antibody, lung, C-reactive protein, nasal, animal model, animal models, immune, Moderate COVID-19, COVID-19 disease, Randomized, serum, Chest CT, COVID-19 infection, immune responses, morbidity, Patient, Control, Mild, morbidity and mortality, medication, disease, anti-CD3, Outpatient, administration, mild to moderate, Mild to moderate COVID-19, reduction, Standard of care, Serum IL-6, pilot study, subject, severe adverse events, immunomodulatory properties, hyperactivity, lung infiltrates, clearance, treated patients, Effect, state, benefit, Dexa, Result, performed, recruited, treated, determine, downregulate, receive, immunomodulatory property, lung infiltrate,